SCHEMBL6360440

SCHEMBL6360440

Cc1ccc(Nc2ccccc2F)cc1C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.48
MEN1 O00255 3/20 0.48
SMN1; SMN2 Q16637 3/20 0.48
GAA P10253 2/20 0.48
NPSR1 Q6W5P4 2/20 0.48
LMNA P02545 1/20 0.48
HTT P42858 1/20 0.48
MAPT P10636 4/20 0.47
RAB9A P51151 3/20 0.47
NPC1 O15118 2/20 0.47
NFKB1 P19838 1/20 0.47
NFKB2 Q00653 1/20 0.47
RELA Q04206 1/20 0.47
TAS2R14 Q9NYV8 1/20 0.42
MAPK14 Q16539 2/20 0.41
MAPK10 P53779 1/20 0.41
KCNJ6 P48051 1/20 0.41
KCNJ5 P48544 1/20 0.41
KCNJ3 P48549 1/20 0.41
TUBB4A P04350 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1921406 0.86 MAPT (0.46) KMT2AMEN1SMN1; SMN2GAALMNA
SCHEMBL22814361 0.82 MAPK13 (0.50) KMT2AMEN1SMN1; SMN2LMNAHTT
SCHEMBL3371377 0.79 MAPT (0.60) KMT2AMEN1SMN1; SMN2GAALMNA
SCHEMBL6355590 0.78 MAPK14 (0.47) KMT2AMEN1SMN1; SMN2GAALMNA
SCHEMBL5492276 0.78 MAPT (0.65) KMT2AMEN1SMN1; SMN2GAALMNA
SCHEMBL18591632 0.76 RAPGEF4 (0.48) KMT2AMEN1SMN1; SMN2NPSR1HTT
SCHEMBL16481326 0.76 ALDH1A1 (0.57) SMN1; SMN2LMNAMAPTRAB9ANPC1
Benzene SCHEMBL7148507 0.75 KMT2A (0.50) KMT2AMEN1SMN1; SMN2GAANPSR1
SCHEMBL11219348 0.75 MAPT (0.60) KMT2AMEN1SMN1; SMN2GAALMNA
SCHEMBL1155655 0.75 ALDH1A1 (0.53) KMT2AMEN1SMN1; SMN2GAALMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6936607-B2 2,4,6-Triaminopyrimidines for the treatment of depression and/or anxiety H. LUNOBECK A/S (DK) 2005-08-30 US disclosed